{"nctId":"NCT01034111","briefTitle":"A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)","startDateStruct":{"date":"2010-03-01","type":"ACTUAL"},"conditions":["Type 2 Diabetes"],"count":30,"armGroups":[{"label":"Sitagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Sitagliptin phosphate","Drug: Metformin"]}],"interventions":[{"name":"Sitagliptin phosphate","otherNames":["MK-0431","Januvia"]},{"name":"Metformin","otherNames":["Glucophage"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants with T2DM failing metformin monotherapy\n* Between the ages of 18 and 79\n\nExclusion Criteria:\n\n* Participants has a history of type 1 Diabetes Mellitus or ketoacidosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Safety and Tolerability of Sitagliptin After 4 Weeks of Treatment","description":"Safety \\& tolerability were measured in terms of the # of participants with \\>=1 adverse event (AE), \\>=1 drug-related AE, \\>=1 serious AE (SAE), or discontinued treatment due to an AE. SAEs included events occurring after initiation of glycemic rescue therapy. AE is defined as any unfavorable/unintended change in structure, function, or chemistry of the body temporally associated with the use of SPONSOR's product. SAE is defined as any AE that results in death, is life-threatening, an overdose, causes or prolongs in-patient hospitalization, or considered medically significant by the investigator.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose at Week 4","description":"Calculated as the mean change from baseline in fasting plasma glucose at Week 4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"2.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Hepatic Enzyme Increased","Decreased Appetite"]}}}